Zug, Switzerland, May 15, 2019 — mymeleon Ltd. is pleased to announce the election of Dr. Christoph von Arb as chairman of the board and Prof. Tariq Mughal as vice-chairman. The unanimous elections of Dr. von Arb and Prof. Mughal foster the vision of mymeleon to be the primary disease prevention company by leading the transition towards health protection, and to enable B2B partners to keep their community of users healthy.
Dr. von Arb’s experience in international affairs and at the interface between academia, industry and government, will nurture mymeleon’s initiative to bring evidence-based scientific know-how and solutions in the prevention of low-grade chronic inflammation to the B2B partners. Professor Mughal, representing the medical community, will ensure that the solutions provided by mymeleon are relevant and contribute in a significant manner to disease prevention and health maintenance.
Patrick Pozzorini, CFO, commented, “I am very pleased that the board elected two of its members as chairman and vice-chairman who perfectly emphasize the vision and mission of mymeleon. Their significant experience in transferring scientific know-how and establishing fruitful partnerships among stakeholders with different backgrounds, are important assets that will ease the growth of mymeleon.”
About Dr. Christoph von Arb
Dr. Christoph A. von Arb is President and Founder of Swiss-based International Initiatives Inc. – TRIPLEYE, a private consulting firm with a specific focus on ERI at the interface between industry, academia and government. He gained his experience in international affairs during his diplomatic service abroad. In the late 90s, he negotiated Switzerland’s full participation in the EU-Research Framework Programs. From 2002 to 2008, Dr. von Arb was Consul-General and Director of the world’s first Digital Science Consulate – swissnex – in Boston, a novel concept of diplomacy based on public-private partnership, which he initiated and implemented. Dr. von Arb is a frequent lecturer at universities and public events and serves on several boards. He received his Ph.D. in Plant Molecular Biology in 1984 from the University of Bern.
About Prof Tariq Mughal
Tariq Mughal qualified in medicine at St George’s Hospital Medical School in London (UK), followed by postgraduate training in Hematology, Medical Oncology and Stem Cell Transplantation at the Imperial College London (Hammersmith Hospital) and the University of Colorado School of Medicine, Denver. He is a Professor of Haematology/Oncology at the Tufts University Cancer Center (Boston) and University of Buckingham (UK). His principal research interests are in precision cancer medicine and hematological malignancies, melanoma and breast cancer. He has published over 130 peer-reviewed papers, 33 cancer textbook chapters and authored/edited 13 cancer books. He is the recipient of a number of awards, including those from the UK Royal College of Physicians, American College of Physicians, Swiss humanitarian groups and a BMA global Book Award. Since 2012, through his foundation, Alpine Oncology Foundation, he has empowered physicians and patients to become eligible for targeted therapies for leukemias, acute and chronic, myeloid and lymphoid, in some of the poorest countries by providing educational support and assistance with diagnostic molecular tools and drug access. He serves as an editorial board member of several peer-led hematology and oncology journals and was the founding co-editor of Clinical Leukemia. He has also helped found several international and national societies.
About mymeleon Ltd.
mymeleon Ltd. is a privately held, science based Swiss technology company. It endeavors to improve people’s health with its anti-inflammaging products and services. Built on a solid foundation by merging state-of-the-art science and AI, it continues the innovative philosophy of the founders who are devoted to keeping communities healthy.
For further information on mymeleon Ltd., please contact email@example.com;
Download file: EN